Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of multiple myeloma according to criteria of the International Myeloma Working Group~* Patients in whom a LEN-DEX-based treatment regimen is indicated~* Adult patients ≥ 19 years of age who are able to freely provide informed consent~Exclusion Criteria:~* Concomitant antiplatelet or anticoagulant use~* Calculated creatinine clearance \< 30 mL/min by Cockcroft-Gault formula~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 times upper limit of normal (ULN)~* Total bilirubin \> 2 x ULN~* Thrombocytopenia \< 50 x 10 gigalitres (Gl)~* High bleeding risk or spontaneously prolonged prothrombin time or activated partial thromboplastin time \> 1.5 x ULN~* Body weight \<50 or \>120 kg~* Concomitant use of CYP3A4 or p-glycoprotein inducers or inhibitors~* Use of Ginkgo biloba or St. John's Wort within 14 days before first dose of study drug~* Dexamethasone use within last 3 months~* Women of Childbearing potential without proper contraceptive measures, pregnancy or breast feeding~* Life expectancy less than 3 months~* Inability to swallow or issues with malabsorption~* Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- apixaban (Type: EXPERIMENTAL): apixaban 2.5 mg PO BID

Based on this trial design, predict the completion outcome and termination type (if applicable).